1. Supplementary Information from A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
- Author
-
Serge Y. Fuchs, Xin-Yuan Liu, Da-Cheng Wang, Guang-Wen Wei, Rong-Bing Guo, Yuliya V. Katlinskaya, Kanstantsin V. Katlinski, Liang Chu, Hai-Neng Xu, Shuai Wu, Jing Xiao, Xian-Long Fang, Su-Jing Yuan, Xi-Jun Liu, Lie-Yang Chen, Yan-Ni Xu, Hui-Ling Li, Yuan-Qin Yang, Xiao-Fei Yin, and Kang-Jian Zhang
- Abstract
Supplementary methods, tables, figures and legends to figures Supplementary Figure 1. The structure of AB loops for sIFN-I and IFNα-2b and comparison on the sequences for sIFN-I and IFNα-21. Supplementary Figure 2. Quantification of phosphorylaiton of STAT1/3 in Figure 3C Supplementary Figure 3. Analysis of the cell surface IFNAR1 levels in the A549-IFNAR1-KO cell clones by FACS. Supplementary Figure 4. sIFN-I shows potent anti-solid tumor effect in immunocompromised mice models. Supplementary Figure 5. sIFN-I treatment decreases cell proliferation and induces senescence in vivo. Supplementary Figure 6. The antitumor effect of sIFN-I in immunocompetent tumor models. Supplementary Figure 7. FACS analysis of splenocytes from tumor-bearing mice treated with sIFN-I. Supplementary Table 1. Primer sequences used in this study. Supplementary Table 2. Primary antibodies used in this study. Supplementary Table 3. The pharmacokinetic index of human IFNα-2b or sIFN-I administered as in Figure 4B was analyzed by WinNonlin version 6.2 software.
- Published
- 2023